FDA Regulatory Wednesday, November 18, 2026 +0.50 Positive

FDA Approves First Treatment for Neurological Symptoms of Type 3 Gaucher Disease

The FDA has approved Infilbray (venglustat), the first medication to treat neurological symptoms of Type 3 Gaucher disease in patients weighing at least 15 kg.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed